Fate Therapeutics opened lower at $1.58, compared with its previous close of $1.61. In the last trading session, the stock traded between $1.25 and $1.59. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Fate Therapeutics is now worth
$ 2.36
Resulting in a loss of
$ 97.64 (97.64%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.27 (-16.82%)
Day High
$1.59
Day Low
$1.25
Day Open
$1.58
Prev Close
$1.61
Volume
35,09,788
1W Return
-36.28%
1M Return
-37.47%
3M Return
-51.15%
6M Return
-38.76%
1Y Return
19.20%
Market Cap ($ Mn)
162
PE Ratio
-
PB Ratio
1.85
PEG Ratio
-
ROE
-52.04%
ROCE
-42.99%
EPS (TTM)
$-0.25
1 Week
-36.28%
1 Month
-37.47%
3 Months
-51.15%
6 Months
-38.76%
9 Months
14.10%
Wells Fargo lowers Fate Therapeutics price target to $3
Wells Fargo lowered Fate Therapeutics' price target from $3.5 to $3. The analyst maintained an Equal-Weight rating on the stock. The revision was made by analyst Yanan Zhu.
6 days agoFate Therapeutics Q3FY26 Results: Net loss narrows 5% YoY to $30.7 million
Net loss narrowed to $30.7 million in Q3FY26 from $32.3 million in Q3FY25. Total operating expenses declined 12% YoY to $32.2 million. Cash runway extended to mid-2028 aided by $15.0 million CIRM grant. FT819 Phase 1 data showed 100% renal response in selected cohort.
7 days agoFate Therapeutics grants 387,000 shares in new employee inducement awards
Fate Therapeutics granted 300,000 stock options at $2.01 exercise price to one new hire. Two new employees received 87,000 restricted stock units (RSUs) combined. Awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). Stock options vest over four years with a one-year cliff followed by monthly vesting. RSUs vest in equal annual installments over four years subject to continuous employment.
9 days agoFate Therapeutics appoints Jamie Harrell as SVP for commercial ops
Jamie Harrell appointed as SVP, Market Development & Commercial Operations effective October 12, 2026. Harrell brings over 25 years of experience and led commercialization of blockbusters like Remicade and Lovenox. New role focuses on commercializing FT819 (lupus nephritis) and FT839 (autoimmune basket trial). Strategy emphasizes outpatient administration to expand CAR T-cell access in community settings.
1mo agoFate Therapeutics grants equity awards to three new hires
Fate Therapeutics granted equity to three new non-executive employees on October 1, 2026. Total awards cover 135,600 shares, split between stock options and RSUs. Stock options priced at $2.30 per share, matching the closing market price. Grants follow Nasdaq Listing Rule 5635(c)(4) for new employee inducements.
1mo agoFate Therapeutics secures $15 million CIRM grant for lupus trial
Fate Therapeutics secured a $15.0 million grant from CIRM under the CLIN2 program. Funding supports the Phase 2 RECLAIM-LN trial of FT819 for lupus nephritis. Trial targets patients refractory to at least two prior systemic immunosuppressive therapies. FT819 is an off-the-shelf CAR T-cell therapy derived from induced pluripotent stem cells.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Fate Therapeutics is now worth
$ 2.36
Resulting in a loss of
$ 97.64 (97.64%)
Note: Past profits do not guarantee future returns.
